Drugmaker developing abuse-deterrent painkiller

The San Diego company that makes the powerful new prescription painkiller Zohydro is selling off its migraine therapy business to focus on developing abuse-resistant forms of Zohydro.

Zogenix Chief Executive Officer Roger Hawley said the sale will help the company focus on the launch of Zohydro ER while providing capital "to continue the development of two abuse-deterrent formulations" of the opioid.

The company announced in November it would pursue an abuse-deterrent form of the drug.

Health officials around the country worry addicts will crush Zohydro capsules and then snort or inject the drug to get high.

Citing such worries, Massachusetts Gov. Deval Patrick tried to ban the drug, but a blocked the state from enforcing the ban. Patrick has since announced new restrictions on the .

4 /5 (2 votes)
add to favorites email to friend print save as pdf

Related Stories

States revolt against powerful new painkiller

Apr 04, 2014

State officials fighting a well-publicized battle against heroin and prescription drug abuse are revolting against a powerful new painkiller that law enforcement and public health officials fear could worsen ...

Sen. Joe Manchin seeks to block new painkiller

Mar 11, 2014

U.S. Sen. Joe Manchin is calling on the government's top health official to overturn the approval of a powerful painkiller, arguing that the pill Zohydro could add to the national epidemic of prescription drug abuse.

Recommended for you

Supercomputers link proteins to drug side effects

Oct 20, 2014

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments